Trial Profile
An Open Label, Multi-center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the continued treatment of patients in the United States currently benefiting or who have benefited from treatment with gefitinib.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2012
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Lung cancer
- Focus Therapeutic Use
- 05 Jun 2012 New trial record